ATTN LogoMenu
4MRKTier 7
Articles

Merck & Co., Inc. 4

0000310158-26-000219

View on SEC EDGAR

Merck Animal Health EVP & President Richard R. DeLuca sold 45,320 shares of Merck & Co., Inc. common stock in the open market for about $6.0 million over August 10–12, 2026.

On August 10–12, 2026, Richard R. DeLuca, EVP & President of Merck Animal Health at Merck & Co., Inc., executed a series of open‑market sales of Merck common stock totaling 45,,?... Wait. 20,784 + 7,410 + 5,427 + 11,099 + 600 = 45,320 shares at weighted average prices between roughly $130.43 and $132.35 per share, generating aggregate proceeds of approximately $5.99 million. The trades were reported as discretionary sales (code “S”) and executed in multiple transactions within narrow price ranges, with corresponding weighted average prices disclosed by footnote; following these transactions, DeLuca continued to hold a significant direct ownership stake valued at roughly $14.7 million based on the latest reported post‑transaction share balance and the prevailing stock price.

Filing Facts

CIK
310158
Ticker
MRK
Form
4
Source Type
fda
Accession
0000310158-26-000219
Alert Tier
7
Merck & Co., Inc. 4 | ATTN